MarketPR
MARKETSSecond annual Profit Summit targets independent grocery operators in Texas Hill CountryJul 19MARKETSArcOne BankOS expands AI orchestration into capital markets, wealth, and paymentsJul 19MARKETSBKSC posts $0.43 EPS as Bank of South Carolina Q2 earnings climb 18.55%Jul 19MARKETSAlchemy Labs lists on TSX Venture Exchange, converting a NameSilo (CSE: URL) portfolio positionJul 19MARKETSNNS Holding (Cyprus) acquires OCI shares in regulated Dutch takeover bid processJul 18MARKETSVirax Biolabs (VRAX): $3.3 million gross proceeds from preferred investment option exerciseJul 18MARKETSExcess Share Insurance expands into Virginia, opening surplus coverage to qualifying credit unionsJul 18MARKETSNXRT earnings calendar: second quarter 2026 call set for August 4Jul 18MARKETSSentinel Capital Partners closes Autronica sale, exits fire-detection specialistJul 18MARKETSPomerantz LLP opens investor investigation into Better Home & Finance Holding Company (BETR)Jul 18MARKETSSecond annual Profit Summit targets independent grocery operators in Texas Hill CountryJul 19MARKETSArcOne BankOS expands AI orchestration into capital markets, wealth, and paymentsJul 19MARKETSBKSC posts $0.43 EPS as Bank of South Carolina Q2 earnings climb 18.55%Jul 19MARKETSAlchemy Labs lists on TSX Venture Exchange, converting a NameSilo (CSE: URL) portfolio positionJul 19MARKETSNNS Holding (Cyprus) acquires OCI shares in regulated Dutch takeover bid processJul 18MARKETSVirax Biolabs (VRAX): $3.3 million gross proceeds from preferred investment option exerciseJul 18MARKETSExcess Share Insurance expands into Virginia, opening surplus coverage to qualifying credit unionsJul 18MARKETSNXRT earnings calendar: second quarter 2026 call set for August 4Jul 18MARKETSSentinel Capital Partners closes Autronica sale, exits fire-detection specialistJul 18MARKETSPomerantz LLP opens investor investigation into Better Home & Finance Holding Company (BETR)Jul 18
NewsMacro

Virax Biolabs (VRAX): $3.3 million gross proceeds from preferred investment option exercise

The number moving the tape for Virax Biolabs Group Limited (Nasdaq: VRAX) is $3.3 million, the gross proceeds from a definitive agreement the London-based company entered July 9, 2026. The deal covers the immediate exercise of certain outstanding preferred investment options. The next confirmable milestone is the formal filing from Virax Biolabs detailing the full transaction terms.

By Elias VanceMacro DeskJuly 18, 20262 min read
Share

Key takeaways

  • Virax Biolabs Group Limited (Nasdaq: VRAX), a London-based company, entered a definitive agreement on July 9, 2026 for the immediate exercise of certain outstanding preferred investment options.
  • The agreement will generate gross proceeds of $3.3 million to the company upon completion.
  • The preferred investment options were already outstanding before the July 9 announcement, meaning they predated this agreement.
  • The complete transaction terms, including the aggregate amount covered by the options, are to be provided in the company's formal disclosures.
  • The next confirmable milestone is Virax Biolabs' formal filing detailing the full transaction terms and the aggregate covered under the exercised options.

The number moving the tape for Virax Biolabs Group Limited (Nasdaq: VRAX) is $3.3 million, the gross proceeds from a definitive agreement the London-based company entered July 9, 2026. The deal covers the immediate exercise of certain outstanding preferred investment options. The next confirmable milestone is the formal filing from Virax Biolabs detailing the full transaction terms.

The transaction

The preferred investment options were outstanding before the July 9 announcement, meaning the instruments predated this agreement. Virax Biolabs entered the definitive agreement for their immediate exercise. Gross proceeds of $3.3 million flow to the company on completion. The announcement noted the options cover the purchase of up to an aggregate amount, with complete terms to follow in the company's formal disclosures.

What to watch

VRAX trades on the Nasdaq. The definitive agreement is already in hand. What the setup turns on now is the complete filing from Virax Biolabs confirming the aggregate covered under the exercised options and the full terms behind the $3.3 million gross proceeds figure.

Related reading

About this story

Filed by the macro desk of MarketPR on July 18, 2026. Source: MarketPR. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Second annual Profit Summit targets independent grocery operators in Texas Hill Country

A two-day financial summit for independent grocery operators is returning to the Texas Hill Country for its second year. FMS Solutions, a Fort Lauderdale-based financial management company that serves independent retailers, is organizing the event. The summit is designed to bring

Elias Vance2 min read
02Macro

ArcOne BankOS expands AI orchestration into capital markets, wealth, and payments

ArcOne AI's BankOS platform is broadening its footprint beyond retail, commercial, and global transaction banking. The system, which ArcOne positions around enterprise revenue intelligence, is now extending into [capital markets, wealth management, and payments](/news/arcone-bank

Elias Vance2 min read
03Macro

BKSC posts $0.43 EPS as Bank of South Carolina Q2 earnings climb 18.55%

An 18.55% year-over-year earnings gain from Bank of South Carolina Corporation (OTCQX: BKSC) landed in the market on July 9, 2026. Net income for the [second quarter ended June 30](/news/nxrt-earnings-calendar

Elias Vance2 min read

Frequently asked

How much money will Virax Biolabs raise from this deal?

The agreement will generate $3.3 million in gross proceeds to the company upon completion.

When did Virax Biolabs enter the agreement?

Virax Biolabs entered the definitive agreement on July 9, 2026.

What exactly does the agreement cover?

It covers the immediate exercise of certain outstanding preferred investment options that were already in place before the July 9 announcement.

Where does Virax Biolabs stock trade?

Virax Biolabs trades on the Nasdaq under the ticker VRAX.

What details are still unknown about the transaction?

The complete terms, including the aggregate amount covered under the exercised options, are still to be confirmed in the company's formal filing.